By: Pooja Toshniwal Paharia, Susha Cheriyedath
New Alzheimer's drugs are raising hopes, but modest benefits, ARIA safety risks, high costs, and regulatory disagreements show how uncertain the path to meaningful treatment remains.
Susha Cheriyedath is a Feature Writer at Azom.com Limited. With nearly two decades of experience in medical communication, she specializes in medicine and healthcare, focusing on topics such as biotechnology, diet and nutrition, and digital health. Susha's work has been featured in various platforms, including AZoQuantum, News Medical, and AZoOptics, reflecting her commitment to staying at the forefront of health and wellness developments.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston


Not enough data
Susha's coverage heavily relies on citing data, indicating a strong preference for evidence-based information. She predominantly covers scientific and healthcare topics, with a focus on health and medicine, genetics, diseases, vaccines, and COVID-19.
For pitching to Susha Cheriyedath:
1. Provide well-researched data-driven insights or studies related to the latest developments in healthcare and medicine.
2. Consider offering interviews with experts who have conducted significant research in the areas of Alzheimer's disease subtypes, long-term effects of COVID-19 on brain function and structure as well as T-cell immunity against SARS-CoV-2 variants.
3. Highlight groundbreaking genetic studies related to insulin resistance and BMI differences across socio-economic groups.
4. Propose information regarding the effectiveness of bivalent COVID-19 vaccines against thromboembolic events or the impact of plant-based diets in reducing COVID risk.
Given her heavy reliance on cited data sources for articles covering scientific and healthcare topics such as new findings about diseases or treatments like Paxlovid for COVID-19 patients—pitching scientifically-backed stories or expert commentary rooted in robust research would likely appeal most to her editorial interests.
This information evolves through artificial intelligence and human feedback. Improve this profile .